| Literature DB >> 35215284 |
Sasinan Bupphathong1, Carlos Quiroz2, Wei Huang3, Pei-Feng Chung4, Hsuan-Ya Tao1, Chih-Hsin Lin1.
Abstract
To recreate or substitute tissue in vivo is a complicated endeavor that requires biomaterials that can mimic the natural tissue environment. Gelatin methacrylate (GelMA) is created through covalent bonding of naturally derived polymer gelatin and methacrylic groups. Due to its biocompatibility, GelMA receives a lot of attention in the tissue engineering research field. Additionally, GelMA has versatile physical properties that allow a broad range of modifications to enhance the interaction between the material and the cells. In this review, we look at recent modifications of GelMA with naturally derived polymers, nanomaterials, and growth factors, focusing on recent developments for vascular tissue engineering and wound healing applications. Compared to polymers and nanoparticles, the modifications that embed growth factors show better mechanical properties and better cell migration, stimulating vascular development and a structure comparable to the natural-extracellular matrix.Entities:
Keywords: GelMA; biomaterials; hydrogel; material modifications; tissue engineering; vascularization
Year: 2022 PMID: 35215284 PMCID: PMC8878046 DOI: 10.3390/ph15020171
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Scheme 1The chemical reaction between gelatin and methacrylate anhydride to produce GelMA and crosslinked GelMA hydrogel.
Figure 1Different modifications of GelMA hydrogel and their benefits.
Summary of GelMA with different modifiers for tissue engineering applications.
| Modifier | Optimal Modifier | Optimal GelMA Concentration | GelMA Crosslinking Condition | Application of Hydrogel | Refs. |
|---|---|---|---|---|---|
| VEGF | 400 ng/mL | 9 | 0.067 | Wound healing in a porcine model | [ |
| VEGF-mimicked peptide | 200 μg/mL | 5 | 0.5 | In vitro microvascularization | [ |
| 100 μg/mL | 2 mg | 0.0002 | In vitro microvascularization | [ | |
| 0.02 | 15 | 1 | Wound healing in a porcine model | [ | |
| AAV-VEGF | 1 × 1010 vg | 20 | 0.5 | Ischemic stroke therapy in a rat model | [ |
| TGF-β3 | 10 ng/mL | 10 | 0.3 | Cartilage regeneration in a rat model | [ |
| 240 ng/construct | 10 | 0.05 | Sustain TGF-β3 supply for chondrogenesis | [ | |
| TGF-β1-affinity peptide | 0.025 mM | 20 | 365 nm UV light, 5 min | Chondrogenesis and cartilage regeneration | [ |
| Platelet lysates | 50 | 7.5 | 0. 0.375% | Angiogenesis in endodontic regeneration | [ |
| 50 | 15 | 0.06 | Skin tissue engineering in a mouse model | [ | |
| Hyaluronic acid | 1 | 15 | 0.3 | Vascularized dermis | [ |
| 5 | 7 | 0.03 | Cartilage regeneration | [ | |
| 5 | 15 | 365 nm UV, 5 min | Skin wound healing | [ | |
| Chitosan | 0.5 and 1 | 10 | 0.1 | Semi- and full-interpenetration network hydrogel | [ |
| 1 | 5 | 0.3 | In vitro 3D neurite outgrowth and elongation | [ | |
| 1 | 3 | 0.25 | Thermo-responsive contraction scaffold for 3D culture | [ | |
| 3 | 15 | Irgacure 2959, 365 nm UV, 5 min | Bone osteogenesis and angiogenesis in a rat model | [ | |
| 2.5 | 2 | Ascorbic acid and H2O2 at 37 °C, ≤60 s | Antibacterial wound closure in a rat model | [ | |
| Alginate | 1 | 1 | 0.25 | Wound healing and soft tissue regeneration | [ |
| 1 | 10 | 1 | Bioprinting blood vessels | [ | |
| 5 | 5 wt% | 0.5 wt% Omnirad 2959, 365 nm UV, 10 min | Antibacterial and bone repair in a mouse model | [ | |
| 4 | 5 | 0.1 | Novel bioink | [ | |
| Silk fibroin | 10 | 10 | 0.1 | Wound healing in a mouse model | [ |
| 1 | 10 | 0.1 mM eosin Y, 0.2 | Novel bioink | [ | |
| 5.6 | 2.4 | 0.1 | Encapsulate cells or growth factors | [ | |
| 8 wt% | 10 wt% | 0.5 | Corneal regeneration | [ | |
| 8 wt% | 10 wt% | 1 | Stroma tissue regeneration | [ | |
| CNT | 0.3 | 7 | 0.5 | The construction of functional engineered cardiac tissues | [ |
| 0.01 | N/A | 0.5 | Cardiac regeneration | [ | |
| rGO | 0.05 | 15 | UV irradiation | Heart-on-a-chip system with dynamic self-reporting function | [ |
| 0.1 | 6 | 0.5 | Conductive scaffold for cardiac microtissue maturation | [ | |
| 0.2 | 20 | 2% | Nerve guidance conduits in a rat sciatic nerve defect model | [ | |
| ND | 0.2 | 7 | 0.1 | Bone regeneration | [ |
| rGO | 0.05 | 15 | UV irradiation | Heart-on-a-chip system with dynamic self-reporting function | [ |
| 0.1 | 6 | 0.5 | Conductive scaffold for cardiac microtissue maturation | [ | |
| SiGO | 0.142 | 15 | 0.15 | Osteogenesis of human mesenchymal stem cells | [ |
| Gold nanorod | 0.01 | 7 | 0.25 | Print 3D cardiac constructs | [ |
| 1.5 | 5 | 0.5 | Maturation and functionalities of the cardiac tissue | [ | |
| Gold nanowires | 0.03 | 10 | 0.5 | Construct functional cardiac tissue | [ |
| Nanosilver | 2 mM | 15 | 0.1 | Treatment for infected bone defects | [ |
| AgNP | 50 μg/ml | 15 | 1.5 | Antibacterial activity for prosthesis | [ |
| HAp | 0.2 | 5 | 1 | In vitro capillary formation for bone tissue engineering | [ |
| Si-HAp | 3 | 15 | 1 | Enhanced the mechanical properties of the composite hydrogel | [ |
| BCP | 10 mg | 15 | 0.05 mM eosin Y, 1.88 | Cell viability and relatively bone differentiation ability | [ |
| MBGNs | 3 | 5 | 1 | Simulate the periosteum and promote bone reconstruction | [ |
| QSC | 3 | 20 | 0.5 | Bone repair with antibacterial properties | [ |
| Laponite | 1 wt% | 7.5 wt% | 1 mM [Ru(dmbpy)3](PF6)2, 10 mM SPS, visible light, 3 min | Osteogenic and angiogenic tissue formation | [ |
| MPEG-PCL | 49.5 | 20 | visible light (405 nm) | Recovery of peripheral nerve injuries | [ |
| GDNF-loaded microspheres | 8 μg/ml | 15 | 200 mM EDC, 10 h | Sciatic nerve growth | [ |
| Dopamine | 30 | 6.25 | 1 | Neural regeneration | [ |
| Polydopamine@SDF-1α | 0.1 | 5 | 0.1 | Stem cell differentiation and repair of focal brain injury | [ |
| PEGDA | 5 | 10 | 1 | Cartilage regeneration | [ |
| 50 | 7 | 0.3 | Novel bioink | [ | |
| PCL | 5 | 5 | Irgacure 2959, UV, 15 min | 3D endothelialization | [ |
N/A—data not available.
Figure 2VEGF-modified GelMA hydrogel. (a) Handheld printing using VEGF-modified GelMA hydrogel as bioink for wound healing (left) and immunostained for von Willebrand Factor under an optical microscope (right) with quantitative results of wound bed angiogenesis by measurement of vWF signal in different wounds (n = 6). The data is presented as mean ± standard error of mean (SEM). Comparison of the different groups was performed using a student’s T test and * represents p < 0.0005 (bottom left). (b) Schematic illustration of GelMA-microneedles loaded with AAV-VEGF and the results of cerebral ischemia treatment in rats among different groups treated. (Photothrombotic (PT), microneedle (MN), adeno-associated virus (AAV), vascular endothelial growth factor loaded microneedle (MN-VEGF)). Statistical analysis was performed using a two-sided Student’s t-test or one-way analysis of variance (ANOVA). of the infarct area (upper right) and the protein levels of VEGF in the brain 3 weeks after MN implantation (lower right). The data are expressed as the mean ± SD. * p < 0.05 and **** p < 0.0001. Reproduced (adapted) with permission from Ref. [23]. 2022 © Biomaterials, and from Ref. [27]. 2021 © Journal of Controlled Release.
Figure 3A schematic illustration of a novel photo-crosslinked GelMA hydrogel and HSNGLPL-MA recruits endogenous TGF-β1 and enhances cartilage regeneration. A 3D reconstruction of micro-computed scans after cartilage repair with GelMA modified with TGF-β1 affine peptides in rabbits. Reproduced (adapted) with permission from Ref. [30]. 2021 © Smart Materials in Medicine.
Figure 4GelMA modified with naturally derived polymers. (a) Hyaluronic acid-modified GelMA for wound therapy from 0–9 days wounds and photographs of wound healing progress. (b) Schematic diagram of GelMA/chitosan wound adhesive doped with dopamine with antibacterial properties and H&E staining on days 7, 14, and 21 observed under an optical microscope. Reproduced (adapted) with permission from Ref. [35]. 2022 © Materials Today Bio, and Ref. [40]. 2020 © Carbohydrate polymers.
Figure 5GelMA modified with naturally derived polymers. (a) Schematic representation of 3D-printed biomimetic blood vessels with alginate modified-GelMA. (b) Silk fibroin-modified GelMA for corneal regeneration with fluorescence imaging DAPI (blue) and rhodamine-phalloidin (red) after 5 days of culture. Reproduced (adapted) with permission from Ref. [42]. 2020 © ACS Applied Materials and Interphases; and Ref. [48]. 2021 © Material Science & Engineering C.
Figure 6GelMA modified by nanomaterials. (a) Carbon nanotubes. (b) Gold nanorods for cardiomyocyte constructs. (c) Biofabrication of silanized hydroxyapatite modified cell-laden GelMA and MG63 cells and human mesenchymal stem cells (MSCs) encapsulation by GelMA composite (green, calcein AM; red, ethidium homodimer-1). Scale bar, 100 µm. Elastic modulus of GelMA-HAp and GelMA-Si-HAp hydrogels data is presented as mean ± standard deviation. * p < 0.05, *** p < 0.001 upon one-way ANOVA analysis (upper right). Reproduced (adapted) with permission from Ref. [50]. 2019 © ACS Nano. Ref [57]. 2017 © Advanced Functional Materials Smart Materials in Medicine. And Ref. [63]. 2021 © Polymers.